Nastech Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Nastech Pharmaceuticals 
Starting stock price: $14.68
Ending stock price: $3.80
Percent Change: -74.11%

Details: Early in 2007 Merck announced that a preliminary study of Nastech's PYY3-36 anti-obesity spray demonstrated no effect and was pulling out of a collaboration to develop the therapy. Then, in November, Nastech took another serious hit after Procter & Gamble pulled out of its efforts on an osteoporosis nasal spray treatment. The company has since announced plans to restructure, including plans to lay off some of its 197 workers.

More News:
Nastech spins off RNAi unit, restructures. Report
Nastech shares wilt after P&G returns drug rights. Report
Nastech to push ahead with obesity spray trial. Report
Nastech hit on missed payment. Report

Nastech Pharmaceuticals - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.